@heal_withb's Ozempic experience raises real concerns
Quick answer
Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.9% in clinical trials. However, 74% of participants in the STEP 1 trial experienced gastrointestinal side effects, with some developing persistent complications like gastroparesis even after discontinuation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok creator claim about Ozempic?
@heal_withb says taking Ozempic was "one of the WORST decisions" she's ever made and that she didn't do proper research beforehand. She also claims doctors haven't been able to help her with side effects or her underlying endometriosis.
The video doesn't specify what negative effects she experienced from semaglutide. She connects her bad experience to broader frustrations with healthcare for chronic conditions like endometriosis and PCOS.
Are serious Ozempic side effects actually documented?
Yes, clinical trials show semaglutide can cause significant side effects that persist even after stopping the medication. The STEP 1 trial (Wilding et al., NEJM, 2021) found 74% of participants experienced gastrointestinal side effects including nausea, diarrhea, and vomiting.
More concerning are emerging reports of gastroparesis (stomach paralysis) that can last months after discontinuation. A 2023 study in JAMA found increased risk of gastrointestinal complications compared to other weight loss medications.
The SUSTAIN trials also documented cases of pancreatitis, gallbladder problems, and kidney issues. These aren't rare outliers but documented risks that some patients experience severely.
Does the healthcare system adequately prepare patients?
This is where the creator makes her strongest point. Many patients report being inadequately counseled about potential long-term effects before starting semaglutide.
The prescribing information lists gastroparesis and other serious side effects, but anecdotal reports suggest rushed consultations don't always cover these thoroughly. The STEP trials required extensive monitoring that often doesn't happen in real-world prescribing.
Her frustration about doctors being unable to help with persistent side effects also rings true. There's limited research on treating post-semaglutide gastroparesis or other lasting complications.
What's missing from her account?
The creator doesn't specify her indication for taking Ozempic or whether she was using it off-label for weight loss versus diabetes management. This context matters for risk-benefit analysis.
She also doesn't detail which specific side effects she experienced or their timeline. Without knowing whether she had gastroparesis, severe nausea, or other documented complications, it's hard to evaluate her experience against known data.
Her comment about not doing research beforehand suggests some personal responsibility, though this doesn't excuse inadequate medical counseling if that occurred.
What should potential users actually know?
The STEP and SUSTAIN trials show semaglutide works for weight loss and diabetes management, but side effects are common and can be severe. About 7% of STEP 1 participants discontinued due to adverse events.
If you're considering semaglutide, ask specifically about gastroparesis risk, gallbladder complications, and what happens if you need to stop suddenly. Get clear protocols for managing side effects before they occur.
The creator's experience with unhelpful follow-up care is unfortunately common. Make sure your prescribing doctor has experience managing semaglutide complications, not just prescribing it.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @heal_withb's Ozempic experience raises real concerns, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.
FormBlends verdict
Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.9% in clinical trials. However, 74% of participants in the STEP 1 trial experienced gastrointestinal side effects, with some developing persistent complications like gastroparesis even after discontinuation.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide (Ozempic) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, leading to average weight loss of 14.9% in clinical trials. However, 74% of participants in the STEP 1 trial experienced gastrointestinal side effects, with some developing persistent complications like gastroparesis even after discontinuation.
- 74% of STEP 1 trial participants experienced gastrointestinal side effects from semaglutide, with 7% discontinuing due to adverse events
- Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- 74% of STEP 1 trial participants experienced gastrointestinal side effects from semaglutide, with 7% discontinuing due to adverse events
- Gastroparesis (stomach paralysis) can persist for months after stopping semaglutide, with limited treatment options available
- The SUSTAIN trials documented increased risks of pancreatitis, gallbladder problems, and kidney complications compared to placebo
- Many patients report inadequate counseling about serious long-term side effects before starting treatment
- Real-world prescribing often lacks the extensive monitoring protocols used in clinical trials
- Ask specifically about gastroparesis risk and post-discontinuation complications before starting semaglutide
- Ensure your prescribing doctor has experience managing semaglutide complications, not just prescribing the medication
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Heal with B · TikTok creator
97.8K views on this video
Going on Ozempic was one of the WORST decisions I’ve ever made. I didn’t do my research. No doctors been able to help me before or since with this or my endo. Americas health care system has failed us
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Heal with B, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.